RxDoctor Payments Data

Mark Ebadi, MD

Allergy/ Immunology · Denver, CONPI 1639140247

Payments from drug & device makers

$2,601in general payments, 2019–2025

Across 130 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$425
  • AstraZeneca$413
  • Sanofi$244
  • Pfizer$237
  • Genentech USA, Inc.$215
  • Regeneron Healthcare Solutions, Inc.$154
  • plus $914 from 16 others

What the payments were for

  • Food & beverage$2,53297%
  • Education$693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$319,799
Medicare patients
672
Services billed
15,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab39$165,499
Advair HfaFluticasone Propion/Salmeterol183$81,104
XolairOmalizumab15$76,609
SymbicortBudesonide/Formoterol Fumarate186$55,390
Qvar RedihalerBeclomethasone Dipropionate77$25,065
Fluticasone-SalmeterolFluticasone Propion/Salmeterol103$18,483
Ipratropium Bromide402$14,963
DuleraMometasone/Formoterol16$8,577
Fluticasone Propionate HfaFluticasone Propionate15$5,440
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$4,264
Epinephrine23$3,891
Albuterol Sulfate HfaAlbuterol Sulfate143$3,845
Arnuity ElliptaFluticasone Furoate14$3,643
Azelastine Hcl47$1,922
Montelukast Sodium140$1,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$413$55,390186 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$30$25,06577 claims
GSKArnuity Ellipta$425$3,64314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Denver

Where these figures come from

Is this you, or does something look wrong? →